UNSPSC 51122804: Zocainone

This classification denotes an antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W8U4S4XLWC. European Medicines Agency schedules Zocainone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00169MIG. Zocainone generally arises in the molecular formula C22H27NO3.

UNSPSC 51122804 Zocainone, a Commodity code, encompasses emergency and critical-care medications that state and local governments—primarily fire rescue services, public health agencies, and multistate cooperative purchasing alliances—procure for immediate use in trauma and cardiac response. Recent solicitations show demand for advanced life support medications supplied as individual units or bulk quantities with strict expiration-date management, direct-to-patient or direct-to-agency delivery, and compliance with FDA, OSHA, and cGMP standards. The City of Tampa Fire Rescue's April 2026 IFB for epinephrine, labetalol, adenosine, and diltiazem vials illustrates the scope: vendors must meet nine-month minimum shelf life from acceptance, warrant 365-day defect-free performance, handle expired-material replacement, and deliver within ten calendar days. Issuing bodies span municipal fire departments, state health and human services commissions, and multistate cooperative purchasing organizations; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinates procurement across multiple states including Oregon, aggregating demand across participating government facilities.

Geographic activity concentrates in Florida and Minnesota with secondary activity in Texas. The City of Tampa's fire-rescue solicitation (IFB 26P00188, due April 8, 2026) for $40,000 estimated value includes a 5 percent local small-business bid discount and mandates WCAG 2.2 accessibility documentation alongside Safety Data Sheets. MMCAP's RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products requires vendors to supply through three authorized wholesalers—AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson—with contract effectiveness July 1, 2026, and a 3 percent administrative fee on all purchases. The Texas Health and Human Services Commission's Request for Information (HHS0017013, posted March 27, 2026) signals emerging demand for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager relationships, though this remains preliminary market research rather than active procurement with budget or timeline commitments.